“The global burden of cancer, limited access to prompt pathology services in many regions and emerging cell profiling technologies increase the need for low-cost, portable and rapid diagnostic approaches that can be delivered at the point of care,” said Cesar Castro, HMS instructor in medicine at Mass General and co-lead author of the report. “The emerging genomic and biological data for various cancers, which can be essential to choosing the most appropriate therapy, supports the need for molecular profiling strategies that are more accessible to providers, clinical investigators and patients. We believe the platform we have developed provides essential features at an extraordinary low cost.”
Get more HMS news here.
The device—called the D3 (digital diffraction diagnosis) system—features an imaging module with a battery-powered LED light clipped onto a standard smartphone. It records high-resolution imaging data with its camera.
With a much greater field of view than traditional microscopy, the D3 system is capable of recording data on more than 100,000 cells from a blood or tissue sample in a single image. The data can then be transmitted for analysis to a remote graphic-processing server via a secure, encrypted cloud service. The results can be rapidly returned to the point of care.
For molecular analysis of tumors, a sample of blood or tissue is labeled with microbeads that bind to known cancer-related molecules; the sample is then loaded into the D3 imaging module. After the image is recorded and data transmitted to the server, the presence of specific molecules is detected by analyzing the diffraction patterns generated by the microbeads.
The use of variously sized or coated beads may offer unique diffraction signatures to facilitate detection. A numerical algorithm developed by the research team for the D3 platform can distinguish cells from beads and analyze as much as 10 MB of data in less than nine-hundredths of a second.
A pilot test of the system with cancer cell lines detected the presence of tumor proteins with an accuracy matching the current gold standard for molecular profiling. The larger field of view enabled simultaneous analysis of more than 100,000 cells at a time.
The investigators then conducted analysis of cervical biopsy samples from 25 women with abnormal Pap smears—samples collected along with those used for clinical diagnosis—using microbeads tagged with antibodies against three published markers of cervical cancer.
Based on the number of antibody-tagged microbeads binding to cells, D3 analysis promptly and reliably categorized biopsy samples as high-risk, low-risk or benign, with results matching conventional pathologic analysis.
D3 analysis of fine-needle lymph node biopsy samples was accurately able to differentiate four patients whose lymphoma diagnosis was confirmed by conventional pathology from another four with benign lymph node enlargement. Along with protein analyses, the system was enhanced to successfully detect DNA—in this instance from human papillomavirus—with great sensitivity.
In these pilot tests, results of the D3 assay were available in under an hour and at a cost of $1.80 per assay, a price that would be expected to drop with further refinement of the system.
“We expect that the D3 platform will enhance the breadth and depth of cancer screening in a way that is feasible and sustainable for resource limited-settings,” said Ralph Weissleder, HMS Thrall Family Professor of Radiology at Mass General, director of the Mass General Center for Systems Biology and co-senior author of the paper. “By taking advantage of the increased penetration of mobile phone technology worldwide, the system should allow the prompt triaging of suspicious or high-risk cases. That could help to offset delays caused by limited pathology services in those regions and reduce the need for patients to return for follow-up care, which is often challenging for them.”
In their further development of this technology, co-senior author Hakho Lee, HMS assistant professor of radiology at Mass General, noted, “The research team will investigate the D3 platform’s ability to analyze protein and DNA markers of other disease catalysts, including infectious agents and allergens, integrate the software with larger databases and conduct clinical studies in settings such as care-delivery sites in developing countries or rural settings and for home testing with seamless sharing of information with providers and/or clinical investigators.”
Mass General has filed a patent application covering the D3 technology.
“Compared with traditional analysis techniques, the D3 mobile platform generates robust biological data while being significantly more cost-conscious, operable by nonspecialist end users and well-suited to point-of-care settings,” said co-lead author Hyungsoon Im, HMS research fellow in radiology at Mass General. “We have field tested the wireless readouts in rural areas of northern New England without problems and believe this technology is poised to deliver fast, low-cost and accurate cancer and HPV diagnosis.”
The study was supported by National Institutes of Health grants R01-HL113156, R01-EB010011, R01-EB00462605A1, T32CA79443 and K12CA087723-11A1; National Heart, Lung and Blood Institute contract HHSN268201000044C; and Department of Defense Ovarian Cancer Research Program Award W81XWH-14-1-0279.
Adapted from a Mass General news release.